Skip to main content

Market Overview

BTIG: Valeant Must Sweeten Allergan Bid To More Than $200/Share

Share:

Allergan's (NYSE: AGN) strong showing in its recent second quarter suggests an acquirer may need to offer "north of $200 a share," one analyst said Tuesday.

Valeant Pharmaceuticals' (NYSE: VRX) $53 billion unsolicited bid for Allergan was rejected last month. The bid equaled $72 in cash and 0.83 per share of Valeant stock for each Allergan share.

Valeant on Monday complained to regulators in the U.S. and Canada, claiming that Allergan had made false statements about sales of some Valeant products in an increasingly bitter takeover battle.

In addition to strong results, Allergan unveiled a $475 million restructuring plan that will cut 1,500 employees and 250 vacant positions.

BTIG's Sean Lavin said resulting savings and an improved outlook should boost Allergan's 2015 earnings to $8.30 per share and 2016 earnings to $10 per share.

"Valeant probably needs to raise it's bid in our opinion," Lavin said in a research note, in which he suggested a price of greater than $200 per share.

Lavin raised his target from $180 to $200 and maintained a Buy rating.

Allergan opened higher Tuesday, but closed down 0.41 percent at $170.43.

Latest Ratings for AGN

DateFirmActionFromTo
Apr 2020SunTrust Robinson HumphreyDowngradesBuyHold
Mar 2020CFRADowngradesBuyHold
Feb 2020SunTrust Robinson HumphreyMaintainsBuy

View More Analyst Ratings for AGN

View the Latest Analyst Ratings

 

Related Articles (AGN)

View Comments and Join the Discussion!

Posted-In: btig Sean LavinAnalyst Color Earnings M&A News Guidance Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com